The Biotechnology Society Hansa Biopharma has published encouraging results from monitoring over five years of patients who participated in the 17-HMEDIDE-14 study, during which they benefited from renal transplantation after desensitization using immlifidase. These data were communicated in a press release.
The results reveal a survival rate of 90 % after five years in patients who received a kidney transplant with Imlifidase.
The survival of the graft, measured as the duration during which an organ or a transplanted fabric continues to successfully operate in the recipient, is 82 %. This figure complies with the results observed three years after transplantation.
“This study has shown for the first time that the HLA incompatible transplant after desensitization by Imlifidase represents an option feasible for patients who need it, with long -term benefits comparable to those of conventional renal transplants. This offers an alternative transformer to pursuit of dialysis, ”comments Hitto Kaufmann, director of research at Hansa Biopharma.
The company will present these results at the International International Congress Congress Congress of the European Organ Transplantation Company, which will be held in London from June 29 to July 2.
